Evidence map›Paper›PMID 32304208›Full record

ArticleAmerican journal of clinical pathology2020

Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources.

Baha Abdalhamid, Christopher R Bilder, Emily L McCutchen, Steven H Hinrichs, Scott A Koepsell, Peter C Iwen

Abstract read
In one paragraph

Article in American journal of clinical pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Baha AbdalhamidDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.
Christopher R BilderDepartment of Statistics, University of Nebraska-Lincoln, Lincoln, NE.
Emily L McCutchenDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.
Steven H HinrichsDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.
Scott A KoepsellDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.
Peter C IwenDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.

Funding

Group testing for infectious disease detection: multiplex assays and back-end screeningR01AI121351 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI BILDER, CHRISTOPHER R · 2016 to 2025
$3.3M
NIAID NIH HHS R01 AI121351
6 · The paper itself

Abstract

objectivesTo establish the optimal parameters for group testing of pooled specimens for the detection of SARS-CoV-2.

methodsThe most efficient pool size was determined to be five specimens using a web-based application. From this analysis, 25 experimental pools were created using 50 µL from one SARS-CoV-2 positive nasopharyngeal specimen mixed with 4 negative patient specimens (50 µL each) for a total volume of 250 µL. Viral RNA was subsequently extracted from each pool and tested using the CDC SARS-CoV-2 RT-PCR assay. Positive pools were consequently split into individual specimens and tested by extraction and PCR. This method was also tested on an unselected group of 60 nasopharyngeal specimens grouped into 12 pools.

resultsAll 25 pools were positive with cycle threshold (Ct) values within 0 and 5.03 Ct of the original individual specimens. The analysis of 60 specimens determined that 2 pools were positive followed by identification of 2 individual specimens among the 60 tested. This testing was accomplished while using 22 extractions/PCR tests, a savings of 38 reactions.

conclusionsWhen the incidence rate of SARS-CoV-2 infection is 10% or less, group testing will result in the saving of reagents and personnel time with an overall increase in testing capability of at least 69%.

Indexed as

BetacoronavirusClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19 TestingHumansMedical Laboratory PersonnelReverse Transcriptase Polymerase Chain ReactionRNA, ViralSARS-CoV-2Specimen HandlingRNA, ViralCOVID-19Group testingSARS CoV-2

Identifiers

PMID32304208
PMCPMC7188150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.